New Treatments

Transforming TB Treatment

TB Alliance is leading the global effort to develop faster, simpler, and more effective cures for all forms of TB.

How We’re Doing It

Learn More:

TB Alliance Announces New Collaboration with Novartis to Advance the Research and Development of Telacebec for Leprosy

TB Alliance and Lupin Announce Collaboration to Advance and Commercialize Telacebec for Multiple Neglected Diseases

TB Alliance and Asian Development Bank Forge Strategic Partnership to Strengthen Regional Efforts Against Tuberculosis

Innovate to Eradicate

For 25 years, TB Alliance has led the global movement to discover, develop, and deliver new and improved TB treatments. After transforming drug-resistant TB therapy, we’re working on a next suite of innovations that could set the stage for ending TB. Our 25th Anniversary series shares perspectives from various thought leaders on the past, present, and future of TB drug development.

Learn More

TB Alliance at the 2025 Union Conference

Join TB Alliance and partners at the 56th Union World Conference on Lung Health, taking place in Copenhagen from 18 – 21 November 2025. Find out more about our presentations and events at the conference.

See Schedule

1a2a2c63fda129964e74e84682d2dadcaa93c79b

The Latest from TB Alliance

Impact of BPaL/M: Shorter Care. More Lives Saved. Lower Costs.

Findings from Johns Hopkins University research show that BPaL/M is on track to save 191k lives and US$1.29B by 2034—while boosting treatment completion and success. Read more.

TB By The Numbers

Million

Tuberculosis (TB) is a global pandemic, killing someone approximately every 24 seconds — about 1.3 million people every year.

Get the Facts

6-Months

Too many people with TB are still given older regimens that take too long to cure, are too complicated to administer, and can be toxic. We are changing this!

How We’re Doing It

+ Projects

Promise in the pipeline means new hope in stopping TB.

Explore our Pipeline